Skip to main content

Peer Review reports

From: Effect of SGLT-2 inhibitor, dapagliflozin, on left ventricular remodeling in patients with type 2 diabetes and HFrEF

Original Submission
18 May 2023 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
29 Aug 2023 Reviewed Reviewer Report
7 Sep 2023 Reviewed Reviewer Report
29 Sep 2023 Author responded Author comments - Lan Cheng
Resubmission - Version 3
29 Sep 2023 Submitted Manuscript version 3
30 Sep 2023 Author responded Author comments - Lan Cheng
Resubmission - Version 4
30 Sep 2023 Submitted Manuscript version 4
4 Oct 2023 Reviewed Reviewer Report
11 Oct 2023 Reviewed Reviewer Report
15 Oct 2023 Reviewed Reviewer Report
25 Oct 2023 Author responded Author comments - Lan Cheng
Resubmission - Version 5
25 Oct 2023 Submitted Manuscript version 5
26 Oct 2023 Reviewed Reviewer Report
26 Oct 2023 Reviewed Reviewer Report
27 Oct 2023 Author responded Author comments - Lan Cheng
Resubmission - Version 6
27 Oct 2023 Submitted Manuscript version 6
31 Oct 2023 Reviewed Reviewer Report
1 Nov 2023 Reviewed Reviewer Report
Resubmission - Version 7
Submitted Manuscript version 7
Publishing
1 Nov 2023 Editorially accepted
8 Nov 2023 Article published 10.1186/s12872-023-03591-3

You can find further information about peer review here.

Back to article page